Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

<p>Abstract</p> <p>Background</p> <p>Epidemiologic studies have suggested that hypertriglyceridemia and insulin resistance are related to the development of colon cancer. Nuclear peroxisome proliferator-activated receptors (PPAR), which play a central role in lipid and...

Full description

Bibliographic Details
Main Authors:	Shemesh Joseph, Tanne David, Motro Michael, Feinberg Micha S, Adler Yehuda, Goldenberg Ilan, Fisman Enrique Z, Boyko Valentina, Tenenbaum Alexander, Schwammenthal Ehud, Behar Solomon
Format:	Article
Language:	English
Published:	BMC 2008-06-01
Series:	Cardiovascular Diabetology
Online Access:	http://www.cardiab.com/content/7/1/18

Similar Items

Long-term effects of peroxisome proliferator-activated receptor ligand bezafibrate on N-terminal pro-B type natriuretic peptide in patients with advanced functional capacity impairment
by: Matas Zipora, et al.
Published: (2009-01-01)

Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons
by: Tenenbaum Alexander, et al.
Published: (2005-09-01)

Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
by: Adler Yehuda, et al.
Published: (2003-11-01)

Update on the use of fibrates: focus on bezafibrate
by: Ilan Goldenberg, et al.
Published: (2008-02-01)

Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
by: Tenenbaum Alexander, et al.
Published: (2012-11-01)

Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR)
by: Fisman Enrique Z, et al.
Published: (2003-03-01)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
by: Fisman Enrique Z, et al.
Published: (2006-09-01)

Bezafibrate for X-linked adrenoleukodystrophy.
by: Marc Engelen, et al.
Published: (2012-01-01)

Metabolic effects of bezafibrate in mitochondrial disease
by: Hannah Steele, et al.
Published: (2020-03-01)

Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.
by: Alexander Tenenbaum, et al.
Published: (2012-01-01)

Statins research unfinished saga: desirability versus feasibility
by: Adler Yehuda, et al.
Published: (2005-06-01)

Bezafibrate prevents aging in in vitro-matured porcine oocytes
by: Ju-Yeon Kim, et al.
Published: (2021-07-01)

Chemical degradation kinetics of fibrates: bezafibrate, ciprofibrate and fenofibrate
by: Marcelo Antonio de Oliveira, et al.

Cardiovascular diabetology in the core of a novel interleukins classification: the bad, the good and the aloof
by: Motro Michael, et al.
Published: (2003-09-01)

Losartan and diabetic nephropathy: commentaries on the RENAAL study
by: Tenenbaum Alexander, et al.
Published: (2002-04-01)

Efficacy of bezafibrate in two patients with mitochondrial trifunctional protein deficiency
by: Tomonori Suyama, et al.
Published: (2020-09-01)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
by: Si-Chi Xu, et al.
Published: (2017-01-01)

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis
by: Yin Q, et al.
Published: (2015-09-01)

Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.
by: C J Packard, et al.
Published: (1990-04-01)

Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia.
by: Farhat L Khanim, et al.
Published: (2009-12-01)

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]
by: Yin Q, et al.
Published: (2015-11-01)

Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes.
by: D Ståhlberg, et al.
Published: (1989-07-01)

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease
by: Klempfner Robert, et al.
Published: (2012-06-01)

Bezafibrate Improves Mitochondrial Fission and Function in DNM1L-Deficient Patient Cells
by: Liza Douiev, et al.
Published: (2020-01-01)

Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy
by: Juliana Geraix, et al.

Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
by: Teramoto Tamio, et al.
Published: (2012-03-01)

Binding of Bezafibrate to Human Serum Albumin: Insight into the Non-Covalent Interaction of an Emerging Contaminant with Biomacromolecules
by: Jiabin Chen, et al.
Published: (2012-06-01)

Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate
by: Sun R, et al.
Published: (2020-01-01)

Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan
by: Kenji Yamada, et al.
Published: (2018-06-01)

Long-term bezafibrate treatment improves skin and spleen phenotypes of the mtDNA mutator mouse.
by: Lloye M Dillon, et al.
Published: (2012-01-01)

Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia
by: Hye-Ri Kang, et al.
Published: (2019-06-01)

In Vitro Studies of the Anti-Leukaemic Activity of Bezafibrate and Medroxyprogesterone Acetate Against Chronic Lymphocytic Leukaemia
by: Hayden, Rachel Elizabeth
Published: (2010)

Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
by: O Leiss, et al.
Published: (1988-09-01)

Assessment of total, ligand-induced peroxisome proliferator activated receptor γ ligand activity in serum
by: Lariah Edwards, et al.
Published: (2019-05-01)

Studies on endogenous regulators and dietary ligands of peroxisome proliferator-activated receptors
by: Goto, Tsuyoshi
Published: (2011)

Biodegradation of bezafibrate by the activated sludge under aerobic condition: Effect of initial concentration, temperature and pH
by: Qian Sui, et al.
Published: (2016-12-01)

Copper and bezafibrate cooperate to rescue cytochrome <it>c</it> oxidase deficiency in cells of patients with <it>sco2</it> mutations
by: Casarin Alberto, et al.
Published: (2012-04-01)

The Study of Estrogen Receptor Ligands and Peroxisome Proliferator Activated Receptor Ligands by Docking and QSAR for Drug Discovery
by: Guan-Yu Chen, et al.
Published: (2008)

Simvastatin and Bezafibrate ameliorate Emotional disorder Induced by High fat diet in C57BL/6 mice
by: Hui Wang, et al.
Published: (2017-05-01)

Effect of Isopropanol on Microstructure and Activity of TiO2 Films with Dominant {001} Facets for Photocatalytic Degradation of Bezafibrate
by: Murtaza Sayed, et al.
Published: (2014-01-01)